Bothell, WA – According to filings with the U.S. Securities and Exchange Commission, Curevo is raising $26,000,004.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, George Simeon played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Curevo
Curevo will combine excellence in protein science and adjuvant technology to speed safe and highly effective vaccines from the bench through clinical development. Curevo will focus on vaccine-preventable illnesses that are common in both the Asian and US markets and for which current vaccine products are not available. Curevos goal is to rapidly advance innovative new vaccine candidates from research laboratory to clinic by joining forces with South Korean Mogam Institute for Biomedical Research, GC Pharma, and the Infectious Disease Research Institute based in Seattle, Washington.

To learn more about Curevo, visit http://www.curevovaccine.com

Contact:
George Simeon, Chief Executive Officer
206-492-5722
https://www.linkedin.com/in/georgesimeon/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved